Azenta vs Bio-Rad Laboratories
Bio-Rad Laboratories reported revenue of $2.6 billion in fiscal 2025, 4.4 times Azenta's $594 million in fiscal 2025. Azenta's revenue grew 3.5% in its latest year, and Bio-Rad Laboratories' grew 0.7%. Azenta had an operating margin of -4.5%, against 1.8% at Bio-Rad Laboratories. Free cash flow was $38 million at Azenta and $375 million at Bio-Rad Laboratories. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.
Side by side
| Azenta | Bio-Rad Laboratories | |
|---|---|---|
| Latest fiscal year | FY2025, Sep 30, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $594M | $2.6B |
| Revenue growth | 3.5% | 0.7% |
| Revenue growth a year, last 5 years | 8.9% | 0.3% |
| Gross margin | 45.5% | 51.9% |
| Operating margin | −4.5% | 1.8% |
| Net margin | −9.4% | 29.4% |
| Free cash flow | $38M | $375M |
| Free cash flow margin | 6.5% | 14.5% |
| Return on capital | — | 0.5% |
| Net debt to EBITDA | — | −1.6x |
| Dividends and buybacks | $0M | $296M |
| Change in diluted share count | −13.7% | −3.3% |
| Last close | $37.17 | $372.43 |
| P/E at the last close | — | 46.6× |
| Insider trades, last 12 months | bought $171,897, sold $0 | sold $349,883 |
| Piotroski F-score | — | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AzentaBio-Rad Laboratories
Operating margin
Percent of revenue
AzentaBio-Rad Laboratories
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AzentaBio-Rad Laboratories
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Azenta and Bio-Rad Laboratories pages.